Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine

Investigative Radiology

Volumn 44, Issue 3, 2009, Pages 135-139

  Hope, Thomas A ^a   Herfkens, Robert J ^b,c   Denianke, Kwame S ^b   LeBoit, Phillip E ^d   Hung, Yun Yi ^e   Weil, Eli ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DIVISION OF RESEARCH   (United States)

Author keywords

Contrast agent; Nephrogenic systemic fibrosis; Prevalence (Invest Radiol 2009; 44: 135 139)

Indexed keywords

CREATININE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

EID: 67651031300     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31819343ba     Document Type: Article

References (26)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. Ting WW, Stone MS, Madison KC, et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903-906.
3. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
4. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-592.
5. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175.
6. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264-267.
7. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198 -1203.
8. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role ofgadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
9. Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179-3185.
10. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
11. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
12. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol. 2008;190:1060-1068.
13. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816.
14. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology. 2008;248:799-806.
15. Information for Healthcare Professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Om-niscan, OptiMARK, ProHance). Available at: http://www.fda.gov/cder/drug/ infosheets/hcp/gcca-200705.htm. Accessed May 13, 2008.
16. Gadolinium-containing MRI contrast agents and Nephrogenic Systemic Fibrosis (NSF)-Update. Available at: http://www.info.doh.gov.uk/doh/embroadcast. nsf/ vwdiscussionall/6F400BE10D03362380257306003452D2. Accessed September 27, 2008.
17. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230-234.
18. Nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD). Available at: http://www.berleximaging.com/html/magnevist/nsf-nfd. html. Accessed September 27, 2008.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
20. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol. 2007;2:200-202.
21. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? MAGMA. 2007;20:57-62.
22. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128-137.
23. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis ofthis condition? Br J Radiol. 2007;80:73-76.
24. Sieber MA, Pietsch H, Walter J, et al. A Preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
25. Magnevist package insert. Available at: http://www.berleximaging.com/ html/ magnevist/product-info.html. Accessed September 27, 2008.
26. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433-3441.